Tag: Inhibrx
Sanofi down after the takeover of Inhibrx, specialist in a rare disease
(AOF) – Sanofi (-1.60% to 92.60 euros) announced the acquisition of INBRX-101, the main asset of Inhibrx, a biotech at the clinical stage specializing in rare diseases. This transaction, estimated…